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coOBJECTIVES The aim of this study was to compare the efﬁcacy of amphilimus-eluting stents (AES) with that of
everolimus-eluting stents (EES) in patients with diabetes mellitus (DM).
BACKGROUND The AES is a polymer-free drug-eluting stent that elutes sirolimus formulated with an amphiphilic
carrier from laser-dug wells. This technology could be associated with a high efﬁcacy in patients with DM.
METHODS This was a multicenter, randomized, noninferiority trial. Patients with DM medically treated with oral glucose-
lowering agents or insulin and de novo coronary lesions were randomized in a 1:1 fashion to AES or EES. The primary
endpoint was the neointimal (NI) volume obstruction assessed by optical coherence tomography at 9-month follow-up.
RESULTS A total of 116 lesions in 112 patients were randomized. Overall, 40% were insulin-treated patients, with a
median HbA1c of 7.3% (interquartile range: 6.7% to 8.0%). The primary endpoint, NI volume obstruction, was
11.97  5.94% for AES versus 16.11  18.18% for EES, meeting the noninferiority criteria (p ¼ 0.0003). Pre-speciﬁed
subgroup analyses showed a signiﬁcant interaction between stent type and glycemic control (p ¼ 0.02), with a signiﬁcant
reduction in NI hyperplasia in the AES group in patients with the higher HbA1c (p ¼ 0.03). By quantitative coronary
angiography, in-stent late loss was 0.14  0.24 for AES versus 0.24  0.57 mm for EES (p ¼ 0.27), with a larger minimal
lumen diameter at follow-up for AES (p ¼ 0.02), mainly driven by 2 cases of occlusive restenosis in the EES group.
CONCLUSIONS AES are noninferior to EES for the coronary revascularization of patients with DM. These results
suggest a high efﬁcacy of the AES and may support the potential beneﬁt of this stent in patients with DM. (A Randomized
Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With
Durable Polymer in Patients With Diabetes Mellitus [RESERVOIR]; NCT01710748) (J Am Coll Cardiol Intv 2016;9:42–50)
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AB BR E V I A T I O N S
AND ACRONYM S
AES = amphilimus-eluting
stent(s)
DES = drug-eluting stent(s)
DM = diabetes mellitus
EES = cobalt chromium
everolimus-eluting stent
NI = neointimal
OCT = optical coherence
tomography
TLR = target lesion
revascularization
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6 Romaguera et al.
J A N U A R Y 1 1 , 2 0 1 6 : 4 2 – 5 0 Amphilimus- Versus Everolimus-Eluting Stents in Diabetes
43P atients with diabetes mellitus (DM) remain athigh risk of in-stent restenosis and adversecardiovascular events despite the use of
drug-eluting stents (DES) (1,2). Second-generation
DES provide superior safety and efﬁcacy results
compared with ﬁrst-generation DES (3,4). However,
stent thrombosis and restenosis rates remain an issue
of continued concern (5).
The amphilimus-eluting stent (AES) is a third-
generation DES devoid of polymer that elutes siroli-
mus formulated with an amphiphilic carrier (so-called
amphilimus) from laser-dug wells on the stent’s
abluminal surface (6). This technology might be
associated with a high efﬁcacy in patients with DM
(7). The aim of this trial was to assess the efﬁcacy of
the AES in patients with DM compared with the cobalt
chromium everolimus-eluting stent with nonerodible
polymer (EES).
METHODS
STUDY DESIGN AND PATIENT SELECTION. A full
description of the trial was previously reported (8).
Brieﬂy, the RESERVOIR (A Randomized Comparison
of Reservoir-Based Polymer-Free Amphilimus-
Eluting Stents Versus Everolimus-Eluting Stents
With Durable Polymer in Patients With Diabetes
Mellitus) trial was a multicenter, prospective, open-
label, assessor-blinded, active treatment–controlled,
randomized clinical trial aimed to compare the results
of AES and EES in patients with DM. This study was
an investigator-driven initiative and was promoted
by the Spanish Society of Cardiology and the Spanish
Heart Foundation.
The target population consisted of diabetic patients
with documented silent ischemia, stable angina,
unstable angina, or non–ST-segment elevation
myocardial infarction. Patients were eligible if they
had a single de novo lesion per coronary artery (in a
maximum of 2 major coronary arteries), with a length
ranging from 12 to 25 mm and a reference diameter of
2.5 to 3.5 mm by visual estimation. The target lesion
had to be treated with a single stent, although addi-
tional stents were allowed in case of suboptimal re-
sults. Major exclusion criteria included ST-segment
elevation myocardial infarction occurring at less than
48 h, left main or ostial left descending artery stenosis,
bifurcations with a side branch >2.5 mm in diameter,BioVentrix, and Boston Scientiﬁc. Dr. Sabate has received a research grant an
an educational grant from the Spanish Society of Cardiology. All other aut
relevant to the contents of this paper to disclose.
Manuscript received September 9, 2015; accepted September 24, 2015.stent restenosis, chronic renal failure with a
glomerular ﬁltration rate <30 ml/min, or a left
ventricular ejection fraction <30%. Patients
with DM treated only with diet and lifestyle
changes were also excluded.
Randomization occurred after successful
pre-dilation and was performed on a 1:1 basis
through an interactive Web response system
(computer-generated sequence allocation),
which was facilitated by an independent con-
tract research organization (Adknoma Health
Research, Barcelona, Spain). There was no
stratiﬁcation. The members of the clinical
events committee and angiographic and opti-
cal coherence tomography (OCT) core laboratory
personnel were blinded to treatment allocation.
The study was performed according to the pro-
visions of the Declaration of Helsinki, and the study
protocol was approved by the ethics committee of
each participating center. Written informed consent
was obtained from all patients.
STUDY DEVICES. The AES (Cre8 coronary stent
system, Alvimedica, Istanbul, Turkey) is a balloon-
expandable stent manufactured from a cobalt chro-
mium L605 alloy with an 80-mm strut thickness and
has an ultrathin (0.3 mm) passive carbon coating. The
AES does not have polymer, and the antiproliferative
drug (sirolimus, 90 mg/cm2) is loaded into reservoirs,
which are dug on the stent’s abluminal surface (6).
The sirolimus is formulated with a mixture of long-
chain fatty acids (so-called amphilimus) to act as a
carrier and to control the drug release. Thus, 65% to
70% of the drug is released within the ﬁrst 30 days,
and the remainder is completely eluted by 90 days (9).
The EES (Xience Prime or Xience Expedition coro-
nary stent system, Abbott Vascular, Abbott Park, Illi-
nois) is a balloon-expandable cobalt chromium L605
stent, with an 81-mm strut thickness. The whole
stent is coated (conformal conﬁguration) with a thin
(7.8 mm), nonerodible and biocompatible ﬂuorinated
copolymer. The polymer is designed to release 80% of
the drug (everolimus, 100 mg/cm2) by 30 days and the
remainder by 120 days (10).
STUDY PROCEDURES. Procedures were performed
according to standard techniques. Successful pre-
dilation was mandatory before randomization.
Post-dilation was encouraged by protocol, although itd speaker fees from Abbott. Dr. Gracida was awarded
hors have reported that they have no relationships
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44was not mandatory. The use of nonstudy stents in
staged procedures at different epicardial vessels was
allowed and was left to the operator’s discretion.
Intraprocedural anticoagulation at the index pro-
cedure was administered according to the current
practice guidelines. The use of glycoprotein IIb/IIIa
inhibitors was left to the operator’s discretion. After
the index procedure, dual antiplatelet therapy was
recommended for 12 months. The use of ticagrelor
(90 mg bid) or prasugrel (10 mg/day) was recom-
mended for acute coronary syndromes if no contra-
indication (11).
Clinical follow-up was performed at discharge,
8 months, and 1 year after the index procedure.
The angiographic and OCT follow-up was scheduled
at 9 months. OCT pullbacks were obtained with the
C7 Dragonﬂy system (St. Jude Medical, St. Paul,
Minnesota) using a nonocclusive technique. A com-
plete metabolic proﬁle including body mass index,FIGURE 1 Study Flowchart
AES ¼ amphilimus-eluting stent(s); DM ¼ diabetes mellitus; EES ¼ ever
tomography; QCA ¼ quantitative coronary angiography.creatinine, HbA1c, and high-density and low-density
lipoprotein cholesterol was assessed in all patients
at baseline and at the angiographic follow-up.
STUDY ENDPOINTS. The primary endpoint was the
neointimal (NI) volume obstruction at 9 months,
assessed by OCT, which is deﬁned as the NI volume
(mm3) divided by the stent volume (mm3) multiplied
by 100. The secondary endpoints included the relative
frequency of uncovered struts, the relative frequency
of malapposed struts, the NI thickness, themaximal NI
area obstruction assessed by OCT (12), and the angio-
graphic in-stent late loss. Although this study was not
powered to compare clinical events, the following
clinical endpoints were also evaluated: ischemia-
driven target lesion revascularization (TLR), target
vessel revascularization, cardiac death, and probable
or deﬁnite stent thrombosis. A full description of all
study endpoints was previously reported (8).olimus-eluting stent(s); FU ¼ follow-up; OCT ¼ optical coherence
TABLE 1 Baseline Characteristics and Metabolic Proﬁle
AES
(n ¼ 56)
EES
(n ¼ 56) p Value
Age, yrs 66.7  9.8 67.2  8.8 0.75
Female 11 (19.6) 17 (30.4) 0.19
Risk factors
Hypertension 46 (82.1) 49 (87.5) 0.43
Hyperlipidemia 45 (80.4) 47 (83.9) 0.62
Ever smoked 30 (53.6) 35 (62.5) 0.33
Metabolic proﬁle
Body mass index 29.6  4.3 29.1  3.4 0.47
HbA1c 7.5  1.2 7.5  1.2 0.80
LDL cholesterol 82.8  39.2 80.7  32.5 0.76
HDL cholesterol 34.4  11.8 36.2  9.2 0.36
Creatinine 0.99  0.26 0.95  0.23 0.34
Vascular complications
Diabetic retinopathy 6 (10.7) 8 (14.3) 0.57
Diabetic nephropathy 9 (16.1) 13 (23.2) 0.34
Previous MI 13 (23.2) 17 (30.4) 0.39
Previous PCI 22 (39.3) 19 (33.9) 0.56
Previous CABG 1 (1.8) 1 (1.8) 1.0
Previous stroke 6 (10.7) 8 (14.3) 0.57
Peripheral artery disease 8 (14.3) 13 (23.2) 0.23
Diabetes treatment
Insulin 21 (37.5) 24 (42.9) 0.56
Biguanides 48 (53.9) 41 (74.5) 0.14
Sulfonylurea 15 (26.8) 14 (25) 0.83
Meglitinides 4 (7.1) 4 (7.1) 1.0
Thiazolidinediones 0 0
a-Glucosidase inhibitors 0 0
Dipeptidyl peptidase
inhibitors
14 (25) 7 (12.5) 0.09
Statins (any) 55 (98.2) 53 (94.6) 0.31
ACE inhibitors 45 (80.4) 39 (69.6) 0.19
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; AES ¼ amphilimus-eluting stent(s);
CABG ¼ coronary artery bypass graft; EES ¼ everolimus-eluting stent(s); HDL ¼
high-density lipoprotein; LDL ¼ low-density lipoprotein; MI ¼ myocardial infarc-
tion; PCI ¼ percutaneous coronary intervention.
TABLE 2 Clinical and Procedural Characteristics
Characteristic
AES,
56 Patients/
58 Lesions
EES
56 Patients/
58 Lesions p Value
Clinical presentation 0.09
Stable 31 (55.4) 22 (39.3)
Acute coronary syndrome 25 (44.6) 34 (60.7)
LV ejection fraction 57.8  9.3 57.7  7.8 0.75
P2Y12 inhibitor 0.27
Clopidogrel 43 (76.8) 49 (87.5)
Prasugrel 11 (19.6) 5 (8.9)
Ticagrelor 2 (3.6) 2 (3.6)
Acetylsalicylic acid 56 (100) 56 (100) 1.00
Glycoprotein IIb/IIIa
inhibitors
0 2 (3.6) 0.15
Radial access 50 (89.3) 49 (87.5) 0.77
No. of vessels diseased 1.61  0.65 1.61  0.73 1.00
Target vessel 0.16
LAD 19 (32.8) 28 (48.3)
LCX 19 (32.8) 17 (29.3)
RCA 20 (34.5) 13 (22.4)
Type B2/C lesion 27 (46.6) 25 (43.1) 0.71
Total contrast volume, ml 236.3  103.2 224.8  67.4 0.48
Total stent length 21.5  6.9 20.7  7.6 0.53
Stent diameter, mm 3.04  0.35 2.93  0.33 0.07
No. of stents per lesion 1.12  0.33 1.05  0.22 0.19
Maximal balloon pressure 16.41  2.8 16.62  2.3 0.65
Post-dilation 14 (23.7) 7 (12.1) 0.10
Angiographic success 58 (100) 58 (100) 1.00
Values are n (%) or mean  SD.
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LV ¼ left
ventricular; RCA ¼ right coronary artery; other abbreviations as in Table 1.
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45ANGIOGRAPHY AND OCT ANALYSIS. Quantitative
coronary angiography analysis was performed at a
central core lab (BARCICORE Lab, Barcelona, Spain)
by experienced analysts blinded to the type of
stent implanted. The analysis was performed using
dedicated coronary angiography analysis software
(CAAS version 5.9, Pie Medical BV, Maastricht, the
Netherlands).
OCT data were also analyzed at a central core lab
(BARCICORE Lab) by experienced analysts blinded to
the type of stent implanted and clinical data, using
proprietary ofﬂine software (LightLab Imaging, St.
Jude Medical). Cross-sections at 1-mm intervals
within the stent segment and 5 mm proximal and
distal to the stent edges were analyzed. Frames with
overlapped stents or side-branch take off were notconsidered for analysis. For totally occluded vessels
that were not associated with stent thrombosis, it was
estimated that the entire length of the stent was ﬁlled
with NI hyperplasia (13).
STATISTICAL ANALYSIS. The study sample size was
determined based on the primary endpoint of 9-month
NI volume obstruction, assuming no difference in
mean. On the basis of previously published data on a
wide population, we expected a NI volume obstruction
of 15.0% for the EES and an SD of 10.7% (14). The
noninferiority margin was set at 5.3% (equaling 35% of
the expected primary endpoint in the EES group) (8).
Given these assumptions, 102 subjects would have
provided an 80% power to demonstrate the non-
inferiority. To account for dropout and to ensure
enough OCT data, w112 patients were eventually
required.
For continuous variables, differences between
groups were evaluated by Student t test, whereas for
discrete variables, chi-square or Fisher exact test was
used. Normality of angiographic and OCT endpoint
TABLE 3 Paired QCA Results
AES
50 Patients/
52 Lesions
EES
49 Patients/
50 Lesions p Value
Before index procedure
RVD, mm 2.69  0.54 2.55  0.49 0.16
MLD, mm 0.92  0.42 0.89  0.34 0.65
Diameter stenosis 66.12  14.88 64.72  12.28 0.61
Curvature, cm1 0.272 (0.133–0.679) 0.361 (0.156–0.549) 0.71
After index procedure
RVD, mm 2.70  0.47 2.64  0.48 0.50
MLD, mm
In-stent 2.51  0.37 2.43  0.36 0.24
In-segment 2.15  0.50 2.06  0.53 0.37
Diameter stenosis
In-stent 8.53  12.82 7.53  8.60 0.68
In-segment 18.82  7.81 19.79  10.51 0.60
Acute gain, mm
In-stent 1.59  0.40 1.54  0.43 0.52
In-segment 1.22  0.46 1.17  0.60 0.59
Curvature, cm1 0.209 (0.107–0.357) 0.197 (0.109–0.400) 0.88
Change in
curvature, cm1
0.070 (0.014–0.385) 0.089 (0.003–0.207) 0.67
9-month follow-up
RVD, mm 2.67  0.45 2.52  0.50 0.13
MLD, mm
In-stent 2.38  0.44 2.19  0.59 0.07
In-segment 2.09  0.45 1.84  0.61 0.02
Late lumen loss, mm
In-stent 0.14  0.24 0.24  0.57 0.27
In-segment 0.06  0.30 0.21  0.61 0.34
Diameter stenosis
In-stent 13.01  10.01 14.69  21.55 0.64
In-segment 19.56  10.58 24.66  17.95 0.08
Binary restenosis*
In-stent 1 (1.9) 2 (4) 0.61
In-segment 2 (3.8) 3 (6) 0.68
Curvature, cm1 0.187 (0.091–0.355) 0.246 (0.098–0.434) 0.39
Values are mean  SD, median (25% to 75% percentile), or n (%). *Diameter stenosis $50%.
MLD ¼ minimal vessel diameter; QCA ¼ quantitative coronary angiography; RVD ¼ reference
vessel diameter; other abbreviations as in Table 1.
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46distribution was veriﬁed by Shapiro-Wilk test, and
the Wilcoxon-Mann-Whitney test was used instead of
the Student t test when appropriate. To account for
the nonindependence of struts within lesions in sec-
ondary endpoints such as the percentage of struts
malapposed or uncovered, generalized estimating
equation models and nonparametric analysis of
aggregated data were used. To explore whether the
results of the primary endpoint were consistent
across important pre-speciﬁed subgroups (treatment
with insulin, higher HbA1c, elevated low-density
lipoprotein cholesterol, low high-density lipoprotein
cholesterol, stent size, and target vessel) (8), a post-
hoc linear regression analysis with formal inter-
action testing was performed. The p value fornoninferiority was 1 tailed, and all other p values
were 2 tailed. Statistical signiﬁcance was set at the
0.05 level for all comparisons. Statistical analyses
were performed using SPSS version 18.0 (SPSS,
Chicago, Illinois).
DATA MANAGEMENT. The investigators designed
the trial and were responsible for its conduct and
analysis. Collected data were entered into an elec-
tronic database, with 100% veriﬁcation against
source data by the contract research organization.
Clinical events were adjudicated by an independent
clinical event committee blinded to the treatment
received.
RESULTS
From October 2012 to October 2013, 112 patients (116
lesions) were enrolled in the study: 56 patients (58
lesions) were assigned to AES and 56 patients (58 le-
sions) were assigned to EES (Figure 1).
Baseline characteristics and metabolic proﬁle were
well matched between groups (Table 1). Overall, 40%
of patients were treated with insulin. The median
HbA1c at baseline was 7.3 (interquartile range: 6.7 to
8.0) and did not change at follow-up (7.3; inter-
quartile range: 6.8 to 8.1), whereas low-density lipo-
protein cholesterol was signiﬁcantly reduced from
baseline to follow-up (mean change, 8.9 mg/dl; 95%
conﬁdence interval: 1.5 to 16.4, p ¼ 0.02), with no
differences between groups. Clinical and procedural
characteristics were also well balanced (Table 2).
Angiographic success was achieved in all cases.
QUANTITATIVE ANGIOGRAPHIC CHARACTERISTICS.
A total of 100 patients (103 lesions) underwent
angiographic follow-up surveillance, with paired data
analyzable for 99 patients (102 lesions). Angiographic
characteristics are shown in Table 3. After stent
implantation, reference vessel diameter, minimal
lumen diameter, and acute gain were similar in both
groups.
At 9-month follow-up, a larger minimal lumen
diameter (mean difference, 0.25 mm; 95% conﬁdence
interval: 0.04 to 0.46 mm, p ¼ 0.02) and a numeri-
cally lower diameter stenosis (p ¼ 0.08) were
observed for AES than for EES. In-stent and
in-segment late lumen loss were, respectively, 0.14 
0.24 for AES versus 0.24  0.57 for EES (p ¼ 0.27)
(Figure 2) and 0.06  0.30 for AES versus 0.21  0.61
for EES (p ¼ 0.34). Stent conformability (change in
curvature) was also similar in both groups.
OPTICAL COHERENCE TOMOGRAPHY. A total of 101
(51 AES, 50 EES) of 103 lesions with invasive follow-up
TABLE 4 Optical Coherence Tomography Results
AES
49 Patients/51 Lesions
(8,280 Struts)
EES
49 Patients/50 Lesions
(8,991 Struts) p Value
Lumen volume, mm3 126.1  59.3 109.3  45.4 0.16
Stent volume, mm3 142.1  63.3 124.4  49.5 0.21
NI volume, mm3 16.0  9.1 15.1  7.6 0.82
Mean NI area stenosis, % 12.1  5.8 16.3  18.2 0.24
Maximal % of lumen stenosis 23.4  11.5 28.4  20.2 0.49
Mean NI thickness, mm 89.6  48.0 87.2  47.5 0.97
Uncovered struts, % 2.2  3.3 3.4  6.9 0.83
Malapposed struts, % 0.9  1.6 1.1  3.9 0.08
Malapposed and uncovered, % 0.6  1.2 0.9  3.8 0.46
Lesions with $5% of 6 (11.8) 8 (17.0) 0.46
FIGURE 2 Cumulative Frequency of In-stent Late Luminal Loss by Quantitative
Coronary Angiography
AES are depicted in red and EES in blue. Abbreviations as in Figure 1.
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47at 9months had analyzable OCT data (1 OCT scan in the
EES group could not be performed due to OCT system
failure, and 1 OCT scan in the AES group was not
analyzable due to poor image quality). Analyzable OCT
data were available in all cases of TLR before any
intervention was performed.
OCT results are presented in Table 4. The primary
endpoint, NI volume obstruction, was 11.97  5.94%
for AES and 16.11  18.18% for EES, reaching the
noninferiority (upper 1-sided 95% conﬁdence inter-
val: 2.6, p for noninferiority ¼ 0.0003, p for
superiority ¼ 0.22) (Figure 3). Post-hoc linear regres-
sion analysis with interaction testing demonstrated
consistency of the results with no signiﬁcant in-
teractions between treatment assignment and OCT
outcomes across 6 pre-speciﬁed groups, with the
exception of patients with HbA1c greater than me-
dian (Figure 4). In this subgroup, AES showed a
signiﬁcantly lower NI volume obstruction than
EES (mean difference, 10.62%; 95% conﬁdence
interval: 22.68% to 1.69%, p ¼ 0.025). Stent
endothelialization was nearly complete in most
cases, with no differences between groups.
CLINICAL OUTCOMES. Clinical follow-up was obtained
for all patients at 12 months (Table 5). No signiﬁ-
cant differences were observed in any of the
pre-speciﬁed endpoints between groups, although
numerically there were more target vessel
revascularizations in the EES group (5.2% vs. 12.1%,
p ¼ 0.18). Importantly, aggressive coronary artery
disease progression was observed, with 1 in every
10 patients in both groups requiring unscheduled
revascularization of a nontarget vessel during the
follow-up.
There was 1 case of deﬁnite late stent thrombosis
(104 days after implantation) in the EES group. This
patient was on dual antiplatelet therapy with clopi-
dogrel, and the cause of the stent thrombosis was
related to severe restenosis. There was 1 unwitnessed
death 13 days after AES implantation that was judged
to be a probable stent thrombosis. One patient in the
AES group underwent unscheduled coronary angiog-
raphy due to progressive angina, which showed
severe stenosis of a jailed diagonal branch (<2.5 mm)
with a patent study stent; the operator decided to
perform kissing balloon angioplasty, and therefore,
although the study stent was widely patent, it was
judged to be a target lesion revascularization.uncovered struts
Lesions with $5% of uncovered
and malapposed struts
2 (4.3) 1 (2.0) 0.61
Values are mean  SD or n (%).
NI ¼ neointimal; other abbreviations as in Table 1.DISCUSSION
In the RESERVOIR study, we compared the efﬁcacy
of a novel elution technology (drug-elution fromlaser-dug wells and formulation with an amphiphilic
carrier) with the classic elution from a durable poly-
mer in patients with DM. Our ﬁndings showed that
AES were not inferior to EES in patients with DM.
The concept of a polymer-free DES is attractive
because the lack of polymer may avoid late events
caused by chronic inﬂammation associated with some
durable polymers (15). However, despite the use of
microporous surfaces, direct application of the drug
FIGURE 4 Analysis of the Primary Endpoint in the Pre-Speciﬁed Var
Pre-speciﬁed subgroup analyses showed a signiﬁcant interaction betwee
HbA1c. CI ¼ conﬁdence interval; DM ¼ diabetes mellitus; HDL ¼ high de
density lipoprotein; other abbreviations as in Figure 1.
FIGURE 3 Cumulative Frequency of Neointimal Volume Obstruction
(Primary Endpoint)
AES are depicted in red and EES in blue. Abbreviations as in Figure 1.
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48to the metallic surface of the stent led in most cases to
fast elution, which was clinically translated to an
impaired antirestenotic efﬁcacy, even with the use of
higher doses of drug than polymer-based DES (16,17).
By contrast, our study shows that drug-elution can be
performed in a timely manner by formulating the
drug with an amphiphilic carrier in the absence of a
polymer. In addition, elution from reservoirs allows
almost all of the drug to be delivered to the vessel
wall, as opposed to DES with polymer in a conformal
conﬁguration (in which a signiﬁcant proportion of the
drug is released to the blood) (9). To the best of our
knowledge, this is the ﬁrst study to show non-
inferiority of a polymer-free DES compared with the
cobalt chromium EES, which is the DES with the most
robust evidence of safety and efﬁcacy in patients with
DM (18,19).
Our study showed a signiﬁcant interaction
between the metabolic control assessed by the HbA1c
and the stent type effect, with a signiﬁcant reduction
of NI hyperplasia in the AES group in poorly
controlled patients. In patients with DM, as glucose
uptake and oxidation are impaired, the heart is forcediables
n the stent type effect and the metabolic control assessed by the
nsity lipoprotein; LAD ¼ left anterior descending artery; LDL ¼ low-
TABLE 5 Clinical Events at 12 Months
Event
AES
56 Patients/
58 Lesions
EES
56 Patients/
58 Lesions p Value
Cardiac death 1 (1.8) 0 1.0
Myocardial infarction 0 1 (1.8) 1.0
Deﬁnite stent thrombosis* 0 1 (1.7) 1.0
Deﬁnite or probable stent
thrombosis*
1 (1.7) 1 (1.7) 1.0
Ischemia-driven target
lesion revascularization*
3 (5.2) 5 (8.6) 0.46
Target vessel revascularization* 3 (5.2) 7 (12.1) 0.18
Unscheduled nontarget
vessel revascularization
6 (10.7) 6 (10.7) 0.99
Values are n (%). *Lesion-based analysis.
Abbreviations as in Table 1.
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49to use fatty acids almost exclusively for adenosine
triphosphate generation. Fatty acid membrane tran-
sporters are overexpressed, resulting in an increased
fatty acid cardiac uptake (20). Thus, it is possible that
the use of fatty acids as a carrier could enhance drug
penetration of insulin-resistant cells, which could
increase its efﬁcacy (21).
Our angiographic and clinical results are consistent
with those of previous studies. A post-hoc analysis of
the NEXT (Multicenter Randomized Trial Comparing
Amphilimus- With Paclitaxel-Eluting Stents in De
Novo Native Coronary Artery Lesions) trial (7)
showed a late loss of the AES in the subgroup of
patients with diabetes of 0.12  0.28 mm, as well as a
TLR frequency up to 12 month <6%. Likewise, the
late loss and need for TLR of the EES are consistent
with those described in the ESSENCE DIABETES
(Randomized Comparison of Everolimus-Eluting
Stent Versus Sirolimus-Eluting Stent Implantation
for De Novo Coronary Artery Disease in Patients
With Diabetes Mellitus) trial (3) or in a post-hoc
analysis of patients with DM of the Comparison of
an Everolimus-Eluting Stent and a Paclitaxel-Eluting
Stent in Patients With Coronary Artery Disease) (22).
Of note, in lesions treated with EES, there was a trend
for a smaller reference vessel diameter and a smaller
stent size than lesions treated with AES, which may
have contributed to the higher late loss.
Importantly, 1 in 10 patients in our trial underwent
unscheduled revascularization of nontarget vessels or
in nonstented segments of the target vessels due to
coronary artery disease progression or plaque desta-
bilization. These ﬁndings are in agreement with those
of previous studies (1) and highlight the particularly
high risk of diabetic patients not only for restenosis
but also for disease progression (23). Thus, regardless
of improvements in DES technology, patients with
DM are likely to remain in the near future at high risk
of cardiovascular events after percutaneous coronary
revascularization (24).
Patients with DM represent 20% to 30% of cases
undergoing percutaneous coronary revascularization
at present. Even so, few interventional studies have
focused on patients with DM, and the endotheliali-
zation pattern after new-generation DES implantation
in diabetic patients is not well understood. Indeed,
the RESERVOIR study is the ﬁrst trial to evaluate the
endothelialization of AES and EES by OCT in these
patients. Our results showed a similar amount of NI
hyperplasia than the general population (14), which
would be consistent with previous intravascular
ultrasound studies performed in the DES era (25).
Thus, after DES implantation, patients with DM
would exhibit similar NI hyperplasia than nondiabeticpatients, and the DES patency at follow-up would be
primarily determined by the smaller lumen post-
procedure (25).
STUDY LIMITATIONS. The present study has limita-
tions that should be acknowledged. This study was
unpowered to detect differences in individual clinical
endpoints between the 2 groups. Moreover, studies
with protocol-mandated late invasive assessment
may overestimate the rate of repeat revasculariza-
tion. Therefore, our ﬁndings should be conﬁrmed or
refuted by larger, longer term follow-up studies in
patients with DM. Finally, all comparisons performed
besides the primary endpoint analysis must be
considered exploratory.CONCLUSIONS
The present study is the ﬁrst to show the non-
inferiority of a polymer-free AES compared with the
EES in patients with DM, and it demonstrates that
formulation of the drug with an amphiphilic carrier
results in noninferior efﬁcacy compared with the
classic elution from SPIRIT III durable polymers.
Results suggest a high efﬁcacy of AES in patients with
DM, which must be conﬁrmed by a large randomized
clinical trial.
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PERSPECTIVES
WHAT IS KNOWN? Patients with DM remain at high
risk of cardiovascular events even with the use of second-
generation polymer-based DES.
WHAT IS NEW? This is the ﬁrst study to show
the noninferiority of a polymer-free DES compared with
the cobalt chromium EES. Formulation of the
antiproliferative drug with an amphiphilic carrier is
associated with a high efﬁcacy in this high-risk
population.
WHAT IS NEXT? Large trials are warranted to ﬁnd the
best stent technology for patients with DM who are not
candidates for surgical revascularization.
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